Jordyn Michelle Thomas

Jordyn Michelle Thomas

Auto-generated profile, based on publicly available information

Jordyn Michelle Thomas

Heart Failure Research Group, Baker Heart and Diabetes Institute, Melbourne, VIC, Australia (J.T., M.D., B.W., S.G., D.M.K.).

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2021 in Hypertension
Verified
Journal Article
Closed access
PDF file
JTJordyn M. Thomas
Jordyn M. Thomas
YLYeong H. Ling
Yeong H. Ling
BHBrooke Huuskes
Brooke Huuskes
MJMaria Jelinic
Maria Jelinic
PSPrerna Sharma
Prerna Sharma
GDGrant R. Drummond
Grant R. Drummond
IL-18 (interleukin-18) is elevated in hypertensive patients, but its contribution to high blood pressure and end-organ damage is unknown. We examined the role of IL-18 in the development of renal inflammation and injury in a mouse model of low-renin hypertension. Hypertension was induced in male C57BL6/J (WT) and IL-18 −/− mice by uninephrectomy, deoxycorticosterone acetate (2.4 mg/d, s.c.) and 0.9% drinking saline (1K/DOCA/salt). Normotensive controls received uninephrectomy and placebo (1K/placebo). Blood pressure was measured via tail cuff or radiotelemetry. After 21 days, kidneys were harvested for (immuno)histochemical, quantitative-PCR and flow cytometric analyses of fibrosis, inflammation, and immune cell infiltration. 1K/DOCA/salt-treated WT mice developed hypertension, renal fibrosis, upregulation of proinflammatory genes, and accumulation of CD3 + T cells in the kidneys. They also displayed increased expression of IL-18 on tubular epithelial cells. IL-18 −/− mice were profoundly protected from hypertension, renal fibrosis, and inflammation. Bone marrow transplantation between WT and IL-18 −/− mice revealed that IL-18-deficiency in non-bone marrow-derived cells alone afforded equivalent protection against hypertension and renal injury as global IL-18 deficiency. IL-18 receptor subunits—interleukin-18 receptor 1 and IL-18R accessory protein—were upregulated in kidneys of 1K/DOCA/salt-treated WT mice and localized to T cells and tubular epithelial cells. T cells from kidneys of 1K/DOCA/salt-treated mice produced interferon-γ upon ex vivo stimulation with IL-18, whereas those from 1K/placebo mice did not. In conclusion, IL-18 production by tubular epithelial cells contributes to elevated blood pressure, renal inflammation, and fibrosis in 1K/DOCA/salt-treated mice, highlighting it as a promising therapeutic target for hypertension and kidney disease.

1 May 2026 in Circulation: Heart Failure
Verified
Journal Article
Open access
JTJordyn Thomas
Jordyn Thomas
MDMisha Dagan
Misha Dagan
BWBIng Wang
BIng Wang
SGSarah Gutman
Sarah Gutman
DKDavid Kaye
David Kaye
Heart failure with preserved ejection fraction is a complex and increasingly prevalent condition often associated with metabolic comorbidities such as obesity, diabetes, and hypertension. Although its burden is substantial, therapeutic progress has lagged compared with heart failure with reduced ejection fraction. GLP-1RAs (glucagon-like peptide-1 receptor agonists), initially developed for glycemic control in type 2 diabetes, have emerged as promising therapeutic agents for the obese/cardiometabolic heart failure with preserved ejection fraction phenotype. Recent trials, including STEP-HFpEF and SUMMIT, have demonstrated improvements in symptoms, quality of life, and reductions in heart failure events. Beyond inducing substantial weight loss, GLP-1RAs exert a range of metabolic, cardiovascular, and anti-inflammatory effects. In this review, we summarize weight-dependent and weight-independent actions of GLP-1RAs and outline how these mechanisms may influence cardiovascular physiology, myocardial remodeling, cardiac metabolism, renal sodium handling, and systemic inflammation in heart failure with preserved ejection fraction.

22 September 2025 in The FASEB Journal
Verified
Journal Article
Open access
JTJordyn M. Thomas
Jordyn M. Thomas
PBPanashe Bamhare
Panashe Bamhare
JMJocelyne Mulangala
Jocelyne Mulangala
CBChristina Bursill
Christina Bursill
SNStephen Nicholls
Stephen Nicholls
KBKristen Bubb
Kristen Bubb
Apolipoprotein C3 (ApoC3) regulates triglyceride metabolism and is associated with accelerated atherogenesis and adverse cardiovascular outcomes. However, its role in peripheral artery disease (PAD) remains unclear. We investigated whether Apoc3 deficiency impacts key features of PAD. Vascularization was assessed using an inflammatory periarterial cuff model (21 days) and a hind limb ischemia model (14 days) in male and female Apoc3 +/+ and Apoc3 −/− mice. Neovascularization was also assessed in mice following extracellular matrix (ECM) plug implantation. Isolated human umbilical vein endothelial cells (HUVECs) were co‐cultured with ApoC3‐stimulated THP‐1 monocytes, and tubule formation was assessed. Apoc3 ‐deficient mice demonstrated less neovessel formation around the cuffed femoral artery, with endothelial cell (CD31+) staining reduced by approximately 40% compared to Apoc3 +/+ mice. Twenty‐four hours after cuff placement, Apoc3 +/+ vessels exhibited increased expression of angiogenic ( Hif1a and Vegf1 ) and pro‐inflammatory ( Cd68 ) markers, while Apoc3 ‐deficient vessels did not. Confirming a role for inflammation in ApoC3‐induced angiogenesis, tubulogenesis of HUVECs increased only in the presence of ApoC3 and THP‐1 monocytes. Apoc3 deficiency, however, did not affect ischemia‐driven angiogenesis, as there were no differences in revascularization compared to Apoc3 +/+ mice, as assessed by the perfusion index (laser Doppler), fibrosis (Picrosirius red staining), or the mRNA expression of apoptotic ( Bax ), angiogenic ( Hif1a and Vegf1 ), and inflammatory ( Ccl2 , Il6 , and Vcam1 ) markers in the ischemic hind limb. Neovascularization following ECM plug implantation was also unaffected by Apoc3 deficiency. In conclusion, ApoC3 contributes to pathological, inflammation‐driven angiogenesis, highlighting its potential as a therapeutic target for pathological angiogenesis without inhibiting physiological ischemia‐driven angiogenesis.

1 January 2022 in SSRN Electronic Journal
Verified
Preprint
Open access
PDF file
JTJordyn Michelle Thomas
Jordyn Michelle Thomas
BHBrooke Huuskes
Brooke Huuskes
CSChristopher Sobey
Christopher Sobey
GDGrant Raymond Drummond
Grant Raymond Drummond
AVAntony Vinh
Antony Vinh
Chronic kidney disease (CKD) is inherently an inflammatory condition, which ultimately results in the development of end stage renal disease or cardiovascular events. Low-grade inflammatory diseases such as hypertension and diabetes are leading causes of CKD. Declines in renal function correlate with elevated circulating pro-inflammatory cytokines in patients with these conditions. The inflammasome is an important inflammatory signalling platform that has been associated with low-grade chronic inflammatory diseases. Notably, activation and assembly of the inflammasome causes the auto cleavage of pro-caspase-1 into its active form, which then processes the pro-inflammatory cytokines pro-interleukin (IL)-1β and pro-IL-18 into their active forms. Currently, the nod-like receptor protein 3 (NLRP3) inflammasome has been implicated in the development of CKD in pre-clinical and clinical settings, and the ablation or inhibition of inflammasome components have been shown to be reno-protective in models of CKD. While clinical trials have demonstrated that neutralisation of IL-1β signalling by the drug anakinra lowers inflammation markers in haemodialysis patients, ongoing preclinical studies are showing that this ability to attenuate disease is limited in progressive models of kidney disease. These results suggest a potential predominant role for IL-18 in the development of CKD. This review will discuss the role of the inflammasome and its pro-inflammatory product IL-18 in the development of renal fibrosis and inflammation that contribute to the pathophysiology of CKD. Furthermore, we will examine the potential of the IL-18 signalling axis as an anti-inflammatory target in CKD and its usefulness as diagnostic biomarker to predict acute kidney injury.